Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embo- lism (PE), is an important cause of morbidity and mortality among patients with cancer.1,2 Patients with cancer are significantly more likely to develop VTE than people without cancer3 and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.4,5Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic pro- phylaxis as well as the effective treatment to reduce the risk of VTE recurrence and mortality. ASCO first pub- lished a guideline on these topics in 2007,6 with updates in 20137 and 2015.8 The 2015 update re-affirmed the 2013 recommendations. The current updaterevises several previous recommendations. Most nota- bly, direct oral anticoagulants (DOACs) have been added as options for VTE prophylaxis and treatment.